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Abstract: Bisphosphonates decrease chondrocyte turnover at the growth plate and impact bone growth. Likewise vascular 
endothelial growth factor (VEGF) plays an important role in endochondral bone elongation by influencing chondrocyte 
turnover at the growth plate. To investigate whether the action of bisphosphonate on the growth plate works through 
VEGF, VEGF protein expression and isoform transcription in endochondral chondrocytes isolated from growing mice and 
treated with a clinically used bisphosphonate, alendronate, were assessed. Alendronate at 10M and 100M 
concentrations decreased secreted VEGF protein expression but not cell associated protein. Bisphosphonates are known to 
inhibit the mevalonate intracellular signaling pathway used by VEGF. Addition of the mevalonate pathway intermediates 
farnesol (FOH) and geranylgeraniol (GGOH) interacted with the low concentration of alendronate to further decrease 
secreted VEGF protein whereas FOH partially restored VEGF protein secretion when combined with the high 
alendronate. Similar to the protein data, the addition of alendronate decreased VEGF mRNA isoforms. VEGF mRNA 
levels were rescued by the GGOH mevalonate pathway intermediate at the low alendronate dose whereas neither 
intermediate consistently restored the VEGF mRNA levels at the high alendronate dose. Thus, the bisphophonate 
alendronate impairs growth plate chondrocyte turnover by down-regulating the secreted forms of VEGF mRNA and 
protein by inhibiting the mevalonate pathway. 
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INTRODUCTION 
  Bisphosphonate drugs inhibit osteoclastic resorption and 
therefore are used to treat bone disease characterized by 
increased osteoclast action [1, 2]. Bisphosphonates are used 
also to regulate circulating vascular endothelial growth factor 
(VEGF) concentrations within the body as a prophylactic 
against cancer metastasis [3]. 
  A major function of VEGF is to modulate endochondral 
chondrocyte turnover during bone growth and development 
[4]. VEGF is synthesized from several isoforms each 
exerting differential effects on endochondral ossification [5]. 
The mature murine VEGF protein is translated from three 
primary transcripts, VEGF 120, VEGF 164, and VEGF 188 
[6], generated by post-transcriptional exon splicing giving 
rise to protein isoforms that differ in extra cellular matrix 
binding affinities. The protein product of VEGF 120 is 
soluble with low binding affinity for extracellular matrix. In 
contrast, the VEGF 164 protein product is partially soluble 
but also binds to extracellular matrix while VEGF 188 is not 
soluble and binds only to matrix proteoglycans. 
  Because angiogenesis is a key element to osteogenesis, 
impairment of vascular invasion alters bone elongation. 
Reduced vascular invasion at the chondro-osseous junction 
has been observed with bisphosphonate treatment [7] 
corroborating the generalized decrease of VEGF and 
vascular expansion observed in bisphosphonate treated   
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cancer patients. Nitrogen containing bisphosphonates such as 
alendronate inhibit the mevalonate pathway that produces 
isoprenoid lipids essential for the cell membrane anchoring of 
small GTP associated proteins (e.g., Ras, Rac, Rho) used in 
intracellular molecular signaling pathways [8]. Bisphosphonate 
treatment spanning the growth phase of juvenile patients may 
impact the events controlling longitudinal bone growth doing so 
by altering VEGF expression as a consequence of disrupting the 
mevalonate pathway. 
  In this study, the effect of a nitrogen containing bisphospho-
nate, alendronate, on VEGF transcript isoform expression and 
VEGF protein production in endochondral chondrocytes was 
assessed. Further, by providing mevalonate pathway intermedi-
ates, the question of how alendronate exerted its action on 
VEGF could be investigated. Characterizing the response of 
VEGF to bisphosphonates may provide insight on the impact of 
therapeutic bisphosphonate treatment on cartilage to bone 
conversion. 
METHODS 
Cell Culture 
  All experimental protocols used in this research were 
reviewed and approved by the institutional animal care and 
use committee of the University of California, Davis. 
Primary chondrocytes were isolated from costochondral 
growth plates of 15 stock inbred C57BL/6J male mice aged 
28 days (Jackson Laboratories, Bar Harbor, ME, USA) as 
previously detailed [9, 10]. The chondrocyte preparation 
was, based on cellular phenotype and previous confirmation 
with density gradients [10], 50% hypertrophic, 40% 
proliferative, and 10% resting cell composition with trypan 
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DMEM/F12 + 10% FBS in 24 well microplates (Corning 
COSTAR, Corning, NY, USA) at a density of approximately 
100,000 cells per ml (2 ml per well) and allowed to recover 
for 48 h. 
  After the initial 48h, media for the primary chondrocytes 
were replaced with DMEM/F12 + ITS media (BD 
biosciences, Bedford, MA, USA) containing 1% FBS. ITS 
media supplements low serum media and maintains 
endochondral chondrocyte growth in culture [11]. A key 
regulator of endochondral bone maturation is insulin like 
growth factor-I (IGF-I) [12] known to preferentially activate 
the p42/p44 MAPK pathway in proliferating growth plate 
chondrocytes by utilizing GTP associated proteins Raf and 
Ras [13]. IGF-I also regulates VEGF expression [13]. Thus 
all media were supplemented with 100ng/ml IGF-I 
(Peprotech Inc., Rocky Hill, NJ, USA) to ensure activation 
of the mevalonate pathway and expression of VEGF. 
  Triplicate chondrocyte cultures were incubated with 
10M or 100M of alendronate either alone or in the 
presence of mevalonate pathway intermediates, 10M 
farnesol (FOH) or 10M geranylgeraniol (GGOH). The 
alendronate concentrations were selected based on 
concentrations experienced by patients and those used in 
culture experiments: estimated cellular concentrations 
experienced by patients receiving bisphosphonates for 
osteoporosis are 10M or less [14] while cultured canine 
fibroblasts and osteosarcoma cells at a wide range of 
alendronate concentrations (1000 to 0.001M) did not impair 
growth or viability [15]. FOH (Alfa Aesar, Ward Hill, MA, 
USA) and GGOH (ICN pharmaceuticals, Aurora, OH) are 
metabolized to farnesylpyrophosphate and geranylgeranyl-
pyrophosphate, essential for the posttranslational modifi-
cations necessary for membrane localization and activation 
of small G-proteins. The 10 M concentration of mevalonate 
intermediates was based on published literature 
demonstrating that this level had no independent effect on 
bone [16]. Cells were incubated with the compounds for 24 h 
prior to collection for VEGF mRNA analysis. The entire 
experiment of 15 animals was fully replicated for treatment 
groups of six independent cultures. 
mRNA Analysis 
  Total RNA was extracted and reverse transcribed for 
real-time PCR of the target VEGF-A gene transcripts 
(VEGF120, VEGF164, VEGF188) using a Taqman assay as 
previously described [10]. The Taqman systems were 
designed to be splice-variant specific by placing the reverse 
primer over the alternatively spliced exon [10]. The 
amplified PCR products were designed to be approximately 
150 base pairs in length. Primer sequences were identified by 
analyzing sequences in GenBank using Vector NTI 9.1 and 
NCBI BLAST software. A universal forward primer was 
used 5’-GGAGAGATGAGCTTCCTACAGCA-3’ for all 
isoforms. The reverse primer was isoform specific: 5’-
CCTCGGCTTGTCACATTTTTCT-3’ (VEGF 120); 5’-GCT 
CACAGTGATTTTCTGGCTT-3’ (VEGF 164); 5’-TCCTC 
GAACTGATTTTTTTTCTGG-3’ (VEGF 188). The Taqman 
probe was 5’-GATGTGAATGCAGACCAAAGAAAGACA 
GG-3’. The amplicons for each isoform were validated by 
agarose gel electrophoresis. To identify the most appropriate 
endogenous control, five commonly used housekeeping 
genes were assessed: a TaqMan PCR system recognizing 
18S rRNA (ssrRNA), GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase), HPRT1 (hypoxanthine phosphoribosyltrans-
ferase 1), B2M (beta 2 microglobulin), and TFR2 (transferrin 
receptor 2; CD71). The murine HPRT1 was selected and 
used as the endogenous control because it was the most 
stably expressed gene for these chondrocytes. Final 
quantitation was done by the comparative CT method (User 
Bulletin no. 2, Applied Biosystems) and is reported as 
relative transcript level relative to a calibrator cDNA. 
Briefly, the signal of the endogenous HPRT1 control was 
used to normalize the target gene signals of each sample. The 
difference in the CT for the target and the CT for the internal 
control, termed CT, was calibrated against the control 
value for cells treated only with ITS plus IGF-I. The relative 
linear amount of target molecules relative to the calibrator, 
was calculated by 2
-Ct; thus, target gene transcript levels 
are expressed as an n-fold difference relative to the calibrator 
level from cells treated with ITS plus IGF-I. 
Protein Analysis 
  Additional triplicate culture wells were treated and the 
media and cell lysates from each treatment group were 
collected 72 h after treatment administration for VEGF 
protein determination. Cells in each well were lysed in 0.1% 
triton-x100 in PBS with the lysates stored at -20 °C; prior to 
assay, lysates were centrifuged and the supernatants 
collected. Total protein content was assayed in media and 
cell lysates using the Bradford colorimetric method. Secreted 
VEGF protein in media and that associated with the cells 
were quantified by the commercially available enzyme-
linked immunosorbent assay according to the manufacturer’s 
directions (Quantikine murine VEGF, R & D Systems, 
Minneapolis, MN, USA) and adjusted for total protein. 
Again, the entire experiment was fully replicated. 
Statistics 
  VEGF protein expression and transcript isoform levels 
across treatments were analyzed by least-squares analysis of 
variance procedures using PROC GLM of SAS (version 8.0, 
2001). Post hoc analyses were done using a Bonferroni 
adjustment. All experiments were replicated fully with the 
experimental replications yielding similar patterns of VEGF 
transcript and protein expression. 
RESULTS 
VEGF Isoforms 
  Growth plate chondrocytes treated with the low dose of 
alendronate (10M) exhibited a 37% decrease in VEGF 120 
and VEGF 164 isoform levels whereas the VEGF 188 
isoform level was unchanged (Fig. 1; p < 0.01). The high 
alendronate dose (100 M) similarly reduced VEGF 120 and 
VEGF 164 isoform levels by 32-36% but also reduced the 
VEGF 188 isoform level to the same extent (Fig. 1;  
p < 0.01). 
  Both VEGF 120 and VEGF 164 transcript levels 
underwent a partial to complete rescue with the addition of 
GGOH in combination with the low alendronate dose, 
whereas the addition of FOH only partially restored the 
VEGF 120 isoform level, but not the 164 transcript. Co-
treatment of the cells with both FOH and GGOH in the Alendronate Inhibits VEGF in the Growth Plate  The Open Orthopaedics Journal, 2009, Volume 3    85 
presence of the low alendronate dose yielded the same 
results as cells treated with GGOH alone (data not shown). 
At the high dose of alendronate, the mevalonate 
intermediates were minimally effective at restoring the 
VEGF transcript levels with only the levels of VEGF 188 
partially restored. In contrast to the results seen for the low 
alendronate dose, only the addition of FOH modestly 
restored VEGF 188 levels; neither FOH nor GGOH restored 
the 120 or 164 isoform levels. Provision of FOH and GGOH 
in combination with the high dose of alendronate was not 
different than either compound alone (data not shown). 
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Fig. (1). VEGF transcript isoform changes in endochondral 
chondrocytes treated with 10 M (A) or 100 M (B) alendronate 
for 24 hours. VEGF n-fold transcription changes for each isoform 
were calibrated relative to ITS +IGF-I control. Gray bars are 
ITS+IGF-I control, red bars are alendronate treated cells, green bars 
are alendronate plus 10M FOH, and blue bars are alendronate plus 
10M GGOH. All values are expressed as least square means ± 
SEM. Within an individual VEGF isoform, bars labeled with 
different letters are significantly different from one another (p < 
0.01). 
 
 
VEGF Protein 
  Total VEGF secreted protein, adjusted for total protein, 
was decreased 32% and 50% by treatment with 10M or 
100M alendronate, respectively (p < 0.001) (Table 1). The 
decrease in VEGF secreted protein induced by the 
alendronate at the low concentration was not restored to 
control levels by the addition of FOH and GGOH. Rather, 
addition of FOH to the 10M dose of alendronate 
significantly decreased VEGF secreted protein beyond that 
observed for alendronate alone, reaching levels comparable 
to that caused by 100M alendronate. The decrease in VEGF 
secreted protein observed in the 100M dose was nearly 
restored by FOH but not by GGOH. This corresponded to 
the rescue seen for the VEGF isoform levels with the 
addition of FOH at the higher alendronate dose. 
  Cell associated VEGF was increased by the 10 M low 
alendronate dose and the addition of the mevalonate pathway 
intermediates did not further augment those levels. In 
contrast, the 100M high alendronate dose did not alter cell 
associated protein but addition of either FOH or GGOH 
reduced VEGF levels, similar to the secreted VEGF response 
for the low alendronate dose. 
DISCUSSION 
  Nitrogen containing bisphosphonate drugs are the 
primary non-surgical treatment for decreasing osteoclast 
action in various bone diseases such as Paget’s disease, 
osteoporosis and osteogenesis imperfecta. Bisphosphonates 
appear to improve tendon repair and prosthetic bone 
surgeries [17, 18] possibly by reducing apoptosis of 
osteoblasts and osteocytes [19]. Further, bisphosphonates 
have been suggested as a preventative for osteoarthritis [20]. 
Bisphosphonate drugs are also used extensively to reduce 
circulating VEGF thereby reducing metastasis for many 
forms of cancer and ameliorate bone pain associated with 
bone cancers [3, 19, 21-24]. Because VEGF is important in 
growth plate chondrocyte turnover and survival [4, 25], 
inhibition of VEGF by prolonged bisphosphonate treatment 
for bone disease or cancer may perturb growth plate 
chondrocyte turnover in juvenile patients.    
  In the present study, alendronate reduced VEGF 
transcript isoform levels and protein expression in 
endochondral chondrocytes by ~ 40%. Such a degree of 
inhibition is likely to have significant biological effects as 
similar reductions achieved by siRNA evoke physiological 
consequences [for example, reference 26]. The VEGF 120 
isoform is the main secreted protein form of VEGF with 
VEGF 164 encoding both a secreted and a membrane bound 
protein and VEGF 188 strictly being membrane bound [27]. 
In the growth plate of juvenile mice the most abundant 
VEGF isoform is the VEGF 120 transcript representing 
76.3% of all VEGF mRNA transcripts, whereas VEGF 164 
and 188 represent 15.3% and 8.4%, respectively [10]. 
Treatment of chondrocytes with the low alendronate dose, 
the dose most similar to clinical studies, preferentially 
decreased the two predominant isoforms responsible for 
secreted protein: VEGF 120 and VEGF 164 without altering  
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VEGF188 mRNA used for the bound form. The individual 
isoforms have distinct roles in angiogenesis and differential 
regulation of VEGF isoform expression has been reported 
for many systems [for example, references 28, 29]. A 
preferential decrease in the secreted VEGF forms by 
alendronate corresponds to the reduced vascular invasion at 
the chondro-osseous junction as seen in vivo following 
treatment with another bisphosphonate, pamidronate [30]. 
  The main mechanism by which nitrogen bisphosphonates 
alter cellular function is through inhibition of various 
enzymes of the mevalonate pathway of isoprenoid lipid 
synthesis [31]. The isoprenoid intermediates farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate are 
essential for the posttranslational modifications necessary for 
membrane anchoring and activation of the small GTP 
associated proteins involved in intracellular signaling. 
Provision of mevalonate pathway intermediates farnesol 
(FOH) and geranylgeraniol (GGOH) have been shown to 
rescue the effects of bisphosphonate mediated inhibition on 
cellular signaling [8, 32-34] thereby providing a mechanism 
to demonstrate whether the alendronate utilized the 
mevalonate pathway in the inhibition of secreted VEGF in 
chondrocytes. 
  Transcript levels of VEGF could be restored at the low 
alendronate concentration with the addition of GGOH 
indicating that transcription was regulated by intracellular 
signaling pathways utilizing geranylgeranylated proteins. 
The levels of VEGF 120 and 164 were increased only 
modestly with the addition of FOH. Though alendronate is 
reported to preferentially alter farnesyl pyrophosphate 
synthase [35, 36] the present study clearly demonstrates that 
low alendronate affects geranylgeranylation in cartilage. At 
the low alendronate dose, reflective of the concentrations 
experienced by patients receiving bisphosphonates [14], the 
present data suggest that geranylgeranylation is the 
preferentially inhibited step in bisphophonate treatment 
within growth plate chondrocytes. 
  The differential response to the mevalonate pathway 
intermediates is similar to findings of alendronate treated 
tumor and bone cells [16, 34]. VEGF mRNA expression is 
known to be regulated by Ras, a farnesylated G protein [37] 
though recent studies suggest that geranylgeranylated Rho 
may also be involved in regulating VEGF expression [38]. 
The data presented here suggest that at low alendronate 
concentrations, geranylgeranylated proteins such as Rho are 
involved in the synthesis of the mRNA forms responsible for 
secreted VEGF. Osteoclasts also rely predominantly upon 
geranylgeranylated proteins for formation and enzymatic 
activity [19] suggesting a coordinate regulation of vascular 
invasion and cartilage resorption at the chondro-osseous 
junction. 
  Low alendronate treatment alone and when combined 
with mevalonate pathway intermediates significantly 
reduced VEGF protein secreted into the media accompanied 
by an increase in cell associated VEGF. These data would 
suggest that alendronate altered the cellular content of both 
farnesylated and geranylgeranylated proteins important in 
the secretory process which in turn impaired release of the 
VEGF protein from the cell. By blocking isoprenoid 
modification, the alendronate may have further reduced the 
capacity of the chondrocyte to secrete VEGF beyond a 
reduction in transcription of the secreted form(s). Blocking 
secreted VEGF and inhibiting osteoclast function by 
reducing geranylgeranylated proteins by alendronate is 
consistent with the impaired vascular invasion and the 
reduced osteoclastic activity seen with bisphosphonates in 
vivo [30]. 
   Vascular invasion is a necessary step in bone elongation 
and reducing that process would be expected to impact bone 
growth. However, reports of children with osteogenesis 
imperfecta given bisphosphonate therapy to reduce fractures 
do not describe negative impacts on bone growth [39]. It is 
possible that some of the G proteins affected by 
bisphosphonate treatment promote proliferation while others 
are involved in signaling pathways driving differentiation 
within the growth plate [40]. If alendronate at a clinically 
relevant dose primarily alters geranylgeranylation, it may 
only impair vascular invasion without negatively affecting 
prenylation steps involved in chondrocyte proliferation. 
Thus, the activity of the growth plate might not be 
significantly reduced, especially in the clinical condition of 
osteogenesis imperfecta where collagen is impaired. In 
contrast, normal rodents given bisphosphonates show 
significantly reduced bone length [7, 30] implying that 
VEGF inhibition has significant consequences on bone 
elongation corroborating the data derived from the VEGF 
knockout mice [5]. This is an important consideration for 
juvenile patients receiving chronic bisphosphonate treatment. 
CONCLUSION 
  Alendronate, a nitrogen containing bisphosphonate, 
reduced secreted VEGF at the mRNA, protein, and secretory 
levels in growth plate chondrocytes indicating that 
Table  1.  VEGF Protein (pg/ml), Adjusted for Total Protein, Secreted into the Media or Cell Associated from Murine 
Endochondral Chondrocytes Treated with Alendronate (ALN) and Mevalonate Intermediates Farnesol (FOH) and 
Geranylgeraniol (GGOH) for 72 h 
 
Media VEGF Protein   Control  ALN  ALN + FOH  ALN + GGOH 
10M ALN  306.9 ± 4.6
a   207.2 ± 4.6
b  132.0 ± 4.6
c  196.3 ± 4.6
b 
100M ALN  279.5 ± 4.6
a  137.8 ± 4.6
c  239.4 ± 4.6
b  105.7 ± 4.6
c 
Cell VEGF Protein  
10M ALN  19.5 ± 1.9
a   34.8 ± 1.9
b  26.4 ± 1.9
a  36.4 ± 1.9
b 
100M ALN  18.6 ± 1.9
a   19.4 ± 1.9
a   9.7 ± 1.9
b  12.4 ± 1.9
b 
Values expressed as LSMEANS ± SEM. Different superscripts within ALN dose (row) indicate means differ (p < 0.001); n = 6 for each different treatment group within a row. Alendronate Inhibits VEGF in the Growth Plate  The Open Orthopaedics Journal, 2009, Volume 3    87 
bisphosphonates inhibit cellular turnover at the chondro-
osseous junction by reducing VEGF induced vascular 
invasion. This study showed that alendronate acted through 
the mevalonate pathway, specifically the geranylgeranylation 
of small GTP associated proteins. Though mRNA isoform 
levels were restored with the provision of mevalonate 
pathway intermediates, VEGF protein was only partially 
restored suggesting additional non-GTP protein associated 
pathways may be involved in the bisphosphonate inhibition 
of secreted VEGF protein. Prolonged inhibition of vascular 
invasion at growth plates reduces bone length. Therefore, the 
benefits derived from bisphosphonate therapy need to be 
weighed against the impact on growth plate function in 
juvenile patients undergoing long-term treatment. 
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